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Introduction: The association of ﬁbromyalgia (FM) and systemic lupus erythematosus (SLE)
has  been investigated, with conﬂicting results regarding the impact of a condition on the
other.
Objectives: To determine the frequency of FM in a sample of patients with SLE treated at the
Hospital Complex of Sorocaba (CHS) and the impact of FM in SLE activity and quality of life,
as  well as of SLE in FM.
Materials and Methods: Descriptive and correlational study. Patients who met the American
College of Rheumatology (ACR) criteria for SLE and/or FM were included. The total sample
was  divided into three groups: FM/SLE (patients with association of SLE and FM), SLE (SLE
patients only) and FM (FM patients only). The following variables were used: Fibromyalgia
Impact Questionnaire (FIQ), activity index of SLE (SLEDAI), Indices of Diagnostic Criteria for
Fibromyalgia 2010 (SSI end GPI) and SF-36.
Results: The prevalence of patients with FM among SLE patients was 12%. FIQ showed no
difference between groups, indicating that SLE did not affect the impact caused by FM alone.
The presence of FM in SLE patients did not inﬂuence the clinical activity of this disease. A
strong impact of FM on the quality of life in patients with SLE was observed; the opposite
was  not observed.
Conclusions: The prevalence of FM observed in SLE patients is 12%. The presence of FMadversely affects the quality of life of patients with SLE.
© 2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: jemartinez@pucsp.br (J.E. Martinez).
ttp://dx.doi.org/10.1016/j.rbre.2014.08.003
255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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A  associac¸ão  ﬁbromialgia  e  lúpus  eritematoso  sistêmico  altera  a
apresentac¸ão  e  a  gravidade  de  ambas  as  doenc¸as?
Palavras-chave:
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Lúpus eritematoso sistêmico
Atividade clínica
Qualidade de vida
Associac¸ão
r  e  s  u  m  o
Introduc¸ão: A associac¸ão da ﬁbromialgia (FM) e de lúpus eritematoso sistêmico (LES) tem
sido  investigada com resultados conﬂitantes em relac¸ão ao impacto de uma condic¸ão na
outra.
Objetivos: Determinar a frequência de FM em uma amostra de pacientes com LES atendidos
no  Conjunto Hospitalar de Sorocaba (CHS) e o impacto da FM na atividade do LES e na
qualidade de vida, bem como do LES na FM.
Material e métodos: Estudo descritivo e transversal. Incluíram-se pacientes que preenchem
os  critérios de classiﬁcac¸ão para LES e/ou de FM do Colégio Americano de Reumatologia
(ACR). A amostra total foi dividida em três grupos: FM/LES (pacientes com associac¸ão LES
e  FM), LES (somente pacientes com LES) e FM (somente pacientes com FM). As seguintes
variáveis foram Questionário de Impacto da Fibromialgia (FIQ), Índice de Atividade do Lúpus
Eritematoso Sistêmico (Sledai), Índices dos Critérios Diagnósticos de Fibromialgia de 2010
(IGS  E IDG) e o SF-36.
Resultados: A prevalência de pacientes com FM entre os pacientes com LES foi de 12%. O
FIQ  não apontou diferenc¸a entre os grupos e indicou que o LES não interferiu no impacto
causado pela FM isoladamente. A presenc¸a da FM em pacientes com LES não inﬂuenciou a
atividade clínica dessa doenc¸a. Observou-se um forte impacto da FM na qualidade de vida
nos pacientes com LES e não foi observado o contrário.
Conclusões: A prevalência de FM observada nos pacientes com LES é de 12%. A presenc¸a de
FM  afeta adversamente a qualidade de vida dos pacientes com LES.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Fibromyalgia (FM) is a rheumatic condition that has as main
features a diffuse chronic pain, hyperalgesia and allodynia.
Fatigue, sleep disturbances, morning stiffness, headache and
paresthesia are symptoms often present.1 Comorbidities like
depression, anxiety, irritable bowel syndrome, myofascial
pain syndrome and nonspeciﬁc urethral syndrome are also
associated.2
This syndrome, whose etiology and pathogenesis have not
been fully elucidated yet, has as its most important mecha-
nism the ampliﬁcation of the transmission of painful stimuli,
with changes in the perception of pain.1 An imbalance in neu-
rotransmitters involved in the physiology of pain was also
observed. Among other abnormalities, na increase of sub-
stance P and nerve growth factor in the cerebrospinal ﬂuid
(CSF) of individuals with ﬁbromyalgia was found.3
Although few Brazilian epidemiological data have been
published, some studies show a prevalence of about 2.5% in
the general population; mostly they are women aged 35–44
years old.4 The mean age of patients is around 29.8 years old.
A relationship with low family income was also noted.5
The clinical assessment can be done through scales of
intensity of symptoms, by speciﬁc instruments to assess the
disease like the Fibromyalgia Impact Questionnaire (FIQ),6 and
by generic questionnaires on quality of life.7
Systemic lupus erythematosus (SLE) is an inﬂammatory
autoimmune disease involving multiple organs, especially the
skin, joints, kidneys, blood vessels, heart and lungs. It is a raredisease, with more  frequent incidence in young women, i.e., in
the reproductive phase, in a ratio of nine to ten women to one
man, and with its prevalence ranging from 14 to 50/100,000
inhabitants.8–12
SLE causes signiﬁcant morbidity and mortality due to
inﬂammatory disease activity, infectious processes secondary
to the disease-induced immunosuppression and its treat-
ment, and to cardiovascular complications.13
The disease assessment can be made by clinical obser-
vation, laboratory tests and imaging studies of the organs
involved, evidence of inﬂammatory activity, evidence relating
to autoimmunity, speciﬁc questionnaires for the assessment
of disease activity such as the Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI)14 and generic questionnaires
to assess quality of life.15
The association of FM and SLE has been investigated by sev-
eral authors, with conﬂicting results regarding the impact of a
condition on the other.16–22 The prevalence of a concomitant
association between the two diseases is around 20%.16 Thus,
the presence of FM in SLE patients is much greater than in the
general population. No study of this association was held in
the Brazilian population; and taking into account the personal
and cultural nature of the impact of chronic diseases on the
quality of life, we  believe that knowing the nature of this asso-
ciation in a Brazilian sample can contribute to this discussion.
The objectives of this study are to determine the presence of
FM in a sample of patients with SLE treated at the Hospital
Complex of Sorocaba (CHS) and the impact of FM on SLE clini-
cal activity and on the quality of life of these patients, as well
as of SLE in FM.
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aterials  and  methods
his is a descriptive cross-sectional study involving patients
rom the Rheumatology outpatient clinic, Sorocaba Hospital
omplex (CHS). Female patients who  met  the American Col-
ege of Rheumatology (ACR) criteria for SLE and/or FM were
ncluded.23,24
The patients were assessed by a rheumatologist who
hecked the fulﬁllment of ACR criteria. The total sample was
ivided into three groups: FM/SLE (patients with an associ-
tion of SLE and FM), SLE (SLE patients only) and FM (FM
atients only).
Data were obtained from medical records and through
nterviews conducted for the questionnaires’ administration,
ince the medical records of patients with SLE did not present
peciﬁc tools for FM;  and the medical records of patients with
M had no speciﬁc tools for LES. Besides these, the following
ata were obtained through questionnaires: disease duration,
linical activity and severity of the disease, and the impact
n the patients’ quality of life. The instruments used in this
ssessment are described below.
The number of patients in each group was determined
y the number of patients with the association of SLE and
M in the outpatient clinic of CHS. Twenty patients were
elected for each group. During the study, patients who were
ost to follow-up with the rheumatologist for unknown rea-
ons were excluded, as well as patients whose data on their
edical records were incomplete and patients whose ques-
ionnaires were not fully answered. There was no refusal by
ny patient to answer the questionnaires. Although the num-
er of subjects in this research can be considered small, the
tudy design aimed to show the reality of a particular ser-
ice and, therefore, a number compatible with the size of the
utpatient clinic where the study was conducted was used.
espite the exclusions, a number of 20 for each group was
eached.
The impact of SLE on FM was evaluated using FIQ,25
hich proved to be a valid and reliable instrument to mea-
ure functional capacity and health status of these patients.
IQ consists of questions that evaluate the difﬁculty that FM
mposes on day-to-day activities, the occupational impact and
he intensity of the main features of the syndrome. The FIQ
otal score ranges from 0 to 100, 0 being the milder impact
nd 100 being the worst impact. This is a speciﬁc instrument;
herefore, it should only be used in groups with patients who
eet the classiﬁcation criteria for FM and not in the SLE-only
roup.
SLEDAI16 was used to evaluate the activity index of SLE
nd the impact that FM may have on this condition, using
linical parameters present in SLE. SLEDAI is a scale that
ssesses 24 variables associated with SLE activity and grouped
nto nine systems, wherein the presence of each commit-
ent receives different weights; thus, weight 8 to lesions of
he central nervous system and vascular injuries; weight 4 for
enal, musculoskeletal and osteoarticular disorders; weight 2
or skin, serous and immunological changes; and weight 1 for
onstitutional and hematological symptoms. The scores were
btained from the medical records on the day the question-
aire was administered. SLEDAI is a speciﬁc instrument; thus, 0 1 5;5  5(1):37–42 39
it should only be used in groups with patients who meet the
classiﬁcation criteria for SLE and not in the FM-only group.
Through the Symptom Severity Index (SSI),26 the severity of
the main symptoms in patients with FM, except for the pain,
was veriﬁed. This questionnaire has a range from 0 to 12, 0
being the lowest and 12 the highest intensity of symptoms.
Generalized Pain Index (GPI)26 was used to evaluate the
extent of pain. GPI shows the number of areas of the body
having pain. This index varies between 0 and 19.
Both GPI and SSI are indexes that comprise the Preliminary
Diagnostic Criteria for Fibromyalgia, 2010.26 By being speciﬁc,
GPI and SSI are instruments that should only be used in groups
of patients who fulﬁll the criteria of classiﬁcation for FM and
not in SLE-only groups.
SF-3627 is a generic questionnaire for assessing the qual-
ity of life, consisting of eight domains: functioning capacity,
physical limitations, general health, vitality, mental health,
and social and emotional aspects. Each scale has a score ran-
ging from 0 to 100, where zero is the worst possible quality of
life and 100 the best QoL scenario.
For the analysis of the results, the following tests were
used: Mann–Whitney test with the aim of comparing the FM
and FM/SLE groups in relation to the FIQ and SSI values; analy-
sis of variance of Kruskal–Wallis for the purpose of comparing
SLE, FM and FM/SLE groups with respect to the values of VAS,
GPI and the eight domains of SF-36; and the chi-squared test
with the aim of comparing SLE, FM and FM/SLE groups with
respect to percentages of presence of hypertension, diabetes
mellitus and osteoarticular diseases.
Results
Sixty patients with FM, SLE and FM associated with SLE
were studied from September 2011 until August 2012, being
distributed equally into three groups, namely, FM, LES and
FM/LES. The prevalence of patients with FM among patients
with SLE followed at CHS was 12%. The average age of the inter-
viewed patients was 44 years for FM group, 40 for SLE group
and 43.5 for FM/LES group.
Similarly, the presence of co-morbidities – diabetes melli-
tus (DM) and systemic arterial hypertension (SAH) – showed
no signiﬁcant difference. The variables “diagnosis of depres-
sion prior to the study” and “other osteoarticular diseases
(OAD)” were more  present in FM-presenting groups (Table 1).
Regarding OAD, patients with FM referred myofascial pain
(5 patients), low back pain (4 patients) and tendinopathy (6
patients). Patients with SLE reported tendinopathy (7 patients)
and low back pain (4 patients). On the other hand, patients of
FM/SLE group mentioned arthritis (1 patient), tendinopathy (7
patients) and low back pain (10 patients).
Table 2 shows the clinical characteristics and impact on
quality of life. The comparison of the impact of ﬁbromyalgia
by FIQ showed no statistically signiﬁcant difference between
FM and FM/SLE groups, indicating that LES did not affect
the impact of FM alone. Although no level of signiﬁcance
(p = 0.0881) was observed, there is a tendency that, in this sam-
ple, patients with FM in association with SLE present a minor
impact on quality of life than those only with FM.
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Table 1 – Clinical data of patients evaluated.
Variables/groups FM SLE SLE/FM P
Age of disease onset (median) 36 28 31.5/35.5 0.0638
Presence of DM (n, %) 2 (10%) 0 1 (5%) 0.3499
SAH (n, %) 6 (30%) 12 (60%) 8 (40%) 0.1496
Presence of OAD (n, %) 15 (75%) 11 (55%) 18 (90%) 0.0426a
Presence of previous depression (n, %) 16 (80%) 3 (15%) 12 (60%) 0.0001a
n; OAn, number; DM, diabetes mellitus; SAH, systemic arterial hypertensio
a FM and SLE/FM > SLE.
Considering that the patients were studied in the tertiary
sector of health care, in the case of patients with ﬁbromyal-
gia we  expect an important participation of emotional issues
such as depression. In the present study it was not possible to
conclude what is the inﬂuence of depression on the quality of
life of the two groups, since this variable has not been studied
with speciﬁc instruments.
Through GPI and SSI, we  observed a greater intensity of
symptoms of ﬁbromyalgia in patients who  only had this
syndrome, in comparison with those FM patients with an
association with SLE. This ﬁnding may explain the tendency
for a lower impact, cited above, observed with the use of FIQ.
The presence of FM in SLE patients did not inﬂuence the clin-
ical activity of this disease, when assessed by SLEDAI.
Regarding the quality of life measured by SF-36, it can be
seen that the groups with FM had a more  negative physical,
social, emotional and mental impact, when compared to the
SLE-only group in all its scales. The domains most affected
by ﬁbromyalgia were physical aspects, pain and emotional
aspects. In SLE patients, this analysis did not detect differ-
ences between domains. On the other hand, in the group
FM/LES the most altered scales were also physical and emo-
tional aspects – thus, a ﬁnding similar to the FM group, again
suggesting a strong inﬂuence of FM in SLE, and not otherwise.Discussion
SLE is an autoimmune disease that can affect various organs,
especially the skin, musculoskeletal system and kidney,
Table 2 – Data from clinical activity and impact on quality of life
Variables/groups FM 
FIQ 71.3 
SLEDAI – 
GPI 15.05 
SSI 10.4 
SF-36 functional capacity
limitations due to
physical aspects
30.75  
Pain 87.5 
General health 17.9 
Vitality 45.5 
Social aspects 21.25 
Limitation due to emotional
aspects
44.43  
Mental health 88.23 
Variables/groups 33.15 D, osteoarticular diseases; p < or > 0.05.
among others.10 The literature has pointed to a higher
prevalence of FM in patients with SLE, than in the general
population. The prevalence identiﬁed of FM in SLE patients
in this study was 12%, slightly lower than that found in the
literature,16–22 ranging from 17 to 22%.
In the evaluation of the characteristics of pain and symp-
tom intensity through VAS, GPI and SSI questionnaires, the
worst performances occurred in the groups presenting FM
alone or in association with SLE. Thus, the presence of FM has
a signiﬁcant negative impact on the quality of life of patients
with SLE. It should be emphasized, however, that most of the
patients pertaining to the group of SLE in this study presented
no disease activity (SLEDAI = zero).
These ﬁndings are in agreement with the literature, since
studies have shown that FM, besides being common in SLE
patients, is the primary determinant of the frequency and
severity of symptoms. In addition, FM causes incapacity for
daily activities.17 Therefore, it is likely that a better control
of FM would result in improvement in the quality of life of
patients with SLE.
In most SF-36 domains, we observed a worse outcome in
the FM-only group. The FM/SLE group showed intermediate
values, which may indicate that FM contributes to the worsen-
ing of health status. These patients are more  symptomatic and
dysfunctional than patients exclusively with LES. Fibromyal-
gia causes a signiﬁcant negative impact on the quality of life of
patients, showing a strong correlation with intensity of pain,
fatigue and decreased functional capacity.18,28,29
According to a Canadian study, the presence of FM in SLE
patients was not related to an increase of the parameters that
.
SLE SLE/FM P
– 59.89 0.0881
0.1 0.3 0.9892
– 11.75 0.0001
– 8.2 0.0152
70.25 48.25 0.0008
35 71.25 0.0004
73.68 37.6 <0.0001
63.25 37.85 0.0067
59.75 33 0.0009
76.25 55.63 0.0023
33.3 73.3 0.0014
70.8 38 0.0003
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ake up SLEDAI; however, the presence of FM has a strong
orrelation with the eight domains of SF-36.29 Thus, FM is not
elated to disease activity in SLE, but can generate a misin-
erpretation of its activity, due to the clinical features of FM,
esides contributing to worsening the quality of life in patients
ith SLE.29
Despite the contribution of FM to the worsening of the
ealth status of patients with SLE, it has been shown in the
iterature that FM causes little or no impact on the activity of
LE,19,29 which corroborates the ﬁndings of our study, where
o change in SLEDAI of respective groups (SLE, FM and SLE/FM)
as noted.
In our study, patients with SLE presented with a stable clin-
cal picture; thus, our results may not reﬂect the reality in the
cute phases of SLE.
The sample of patients with both FM and SLE differs in
elation to what is observed in the community. Patients with
M are those individuals refractory to a standard treatment,
ince they are seen at a tertiary level center, while SLE patients
re generally treated at tertiary centers. Therefore, our sam-
le may not reﬂect the general population of patients with
bromyalgia. A complement to this study intends to propose
he assessment of patients seen at primary and secondary
ectors.
onclusion
he frequency of FM observed in patients with SLE treated
t CHS is 12%. The patients had a mean age of 40–44 years
n the three groups. The presence of SLE has not determined
 greater impact on quality of life of patients with SLE/FM,
hen assessed by FIQ. FM,  in turn, also did not result in higher
evels of LSE activity measured by SLEDAI. A higher intensity of
ymptoms in the FM-only group, in relation to the association
LE/FM, was noted. The presence of FM adversely affects the
uality of life of patients with SLE.
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